Abstract
This systematic review investigated almitrine-raubasine combination (brand name Duxil) as an alternative treatment for dementia.
There was insufficient evidence to support the routine use of Duxil for the treatment of patients with dementia, due to the low methodological quality of trials available so far, the small number of these trials and their probable publication bias. High-quality and large-scale randomised controlled trials are needed.
Reference
Yang, W. Liu, M. [and] Teng, J. [et al] (2011). Almitrine-Raubasine combination for dementia. Cochrane Database of Systematic Reviews (Online), March 16th 2011, Issue No.3, No.CD008068. (Click here to view the PubMed abstract).
